Erratum: The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells (Diabetologia DOI 10.1007/s00125-013-3067-x);The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells

Diabetologia

Volumn 57, Issue 1, 2014, Pages 187-191

  Oram, Richard A ^a   Jones, Angus G ^a   Besser, Rachel E J ^a   Knight, Bridget A ^a   Shields, Beverley M ^a   Brown, Richard J ^b   Hattersley, Andrew T ^a   McDonald, Timothy J ^a,b  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

C peptide; Insulin; Microsecretor

Indexed keywords

C PEPTIDE; CREATININE;

ADOLESCENT; ADULT; ARTICLE; CHEMOLUMINESCENCE; CHILD; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC PATIENT; DIET RESTRICTION; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; SCHOOL CHILD; STIMULATION; STIMULUS; TEST MEAL; URINALYSIS; YOUNG ADULT;

ADULT; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; YOUNG ADULT;

EID: 84890999355     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-3103-x     Document Type: Erratum

References (17)

1. Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264
2. Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832-836
3. Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31:1966-1971
4. Besser RE, Shields BM, Casas R, Hattersley AT, Ludvigsson J (2013) Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 36:195-201
5. Nordwall M, Ludvigsson J (2008) Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years. Diabetes Metab Res Rev 24:472-479
6. Wang L, Lovejoy NF, Faustman DL (2012) Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 35:465-470
7. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48:2221-2228
8. Keenan HA, Sun JK, Levine J et al (2010) Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59:2846-2853
9. Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619-633
10. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS (1986) The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29:267-274
11. McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT (2009) Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 55:2035-2039
12. Besser RE, Ludvigsson J, Jones AG et al (2011) Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 34:607-609
13. Jones AG, Besser RE, McDonald TJ et al (2011) Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med 28:1034-1038
14. (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 128:517-523
15. Besser RE, Shepherd MH, McDonald TJ et al (2011) Urinary C-peptide creatinine ratio (UCPCR) is a practical outpatient tool for identifying HNF1A/HNF4A MODY from long duration type 1 diabetes. Diabetes Care 34:286-291
16. Wiedmeyer HM, Polonsky KS, Myers GL et al (2007) International comparison of C-peptide measurements. Clin Chem 53:784-787
17. Little RR, Rohlfing CL, Tennill AL et al (2008) Standardization of C-peptide measurements. Clin Chem 54:1023-1026